Stock Market & Financial Investment News

News Breaks November 11, 2012 12:09 EDT VRTX Vertex presents new Phase 3 data on HCV treatment with twice-daily telaprevir Vertex Pharmaceuticals announced that new data from a Phase 3 study in people being treated for hepatitis C for the first time showed similar rates of viral cure (SVR12, HCV RNA levels < 25 IU/mL 12 weeks after the end of all treatment) when telaprevir was given twice daily compared to three times daily, the currently approved dosing schedule. Telaprevir is approved for use in combination with pegylated-interferon and ribavirin by the U.S. Food and Drug Administration, FDA, and Health Canada under the brand name INCIVEK® (telaprevir) tablets for people with genotype 1 chronic hepatitis C virus, HCV, with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). In addition, new data from a Phase 2 study demonstrated that approximately three of four people co-infected with HCV and HIV achieved an HCV viral cure (SVR24, HCV RNA levels < 25 IU/mL 24 weeks after the end of all treatment) with telaprevir combination treatment. These and other new data on Vertex’s medicines in development for hepatitis C were presented at The Liver Meeting®, the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, AASLD. News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 19, 2013 12:06 EDT VRTX Options with decreasing implied volatility: DISH VRTX SUPN S Subscribe for More Information June 18, 2013 11:43 EDT VRTX Options with decreasing implied volatility: PVH VRTX EWG Subscribe for More Information 08:36 EDT VRTX Elan shares could be worh $19 in a buyout, says Jefferies Jefferies raised its price target for shares of Elan (ELN) to $19 from $14, reflecting what it sees as the value of the company in a takeout scenario. The firm says Elan management suggested they would be open to sale in the $15-$20 per share range. Jefferies believes a high taxpaying suitor could pay the upper end of that range, and lists Allergan (AGN), Regeneron (REGN), Vertex (VRTX), Alexion (ALXN), Zoetis (ZTS), Mylan (MYL) and Perrigo (PRGO) as potential acquirers for Elan. Shares of Elan are up 13c to $13.62 in pre-market trading after Royalty Pharma announced that its buyout proposal for the company has expired. June 17, 2013 07:28 EDT VRTX Cambridge Healthtech Institute to host a conference Subscribe for More Information June 14, 2013 09:38 EDT VRTX Vertex has a conference call hosted by JPMorgan Subscribe for More Information 07:25 EDT VRTX Vertex CF data positive, says RBC Capital RBC Capital believes that data on Vertex's CF drug looked good and lowers the risk of the treatment. The firm expects the company to report good Phase III results for the drug in summer 2014, and it reiterates an Outperform rating on the stock. June 12, 2013 07:33 EDT VRTX European Cystic Fibrosis Society to host a conference 36th ECFS Conference is being held in Lisbon, Portugal on June 12-15. June 11, 2013 14:37 EDT VRTX SMC posts decision on Kalydeco resubmission to website Subscribe for More Information 07:31 EDT VRTX Goldman to host a conference Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.